Juno reports Phase I data for JCAR017 in NHL

Juno Therapeutics Inc. (NASDAQ:JUNO) reported data from 54 evaluable patients with relapsed or refractory B cell non-Hodgkin's lymphoma (NHL) in the Phase I TRANSCEND NHL 001 trial showing that JCAR017 led to a best overall response rate (ORR) of 76%, including 28 complete responses. The 3-month ORR and complete response rates were 51% and 39%, respectively. Cytokine release syndrome (CRS) occurred in 35% of patients. The most common treatment-emergent adverse events reported were neutropenia, CRS and fatigue.

In the "core analysis" of 44 patients which includes patients with diffuse large B cell lymphoma (DLBCL) de novo and transformed from follicular lymphoma with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, JCAR017 led to an ORR of 86%, including 26 complete responses. The 3-month ORR and complete response rates were 66% and 50%, respectively. Next half, Juno plans to start a pivotal trial of JCAR017 in the "core analysis" population. Data were presented at the American Society of Clinical Oncology meeting in Chicago...